We further investigated the effects of induced CD133 expression and consequent AREG upregulation on cell proliferation and cell growth in patient-derived human melanoma cells and tested the feasibility of targeting AREG by siRNA and eventually small molecule or antibody-based inhibitors. Here, PROM1 is linked to melanoma.